Ryo Ko

1.1k total citations
60 papers, 547 citations indexed

About

Ryo Ko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Ryo Ko has authored 60 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 9 papers in Neurology. Recurrent topics in Ryo Ko's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (23 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Ryo Ko is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (23 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Ryo Ko collaborates with scholars based in Japan, United Kingdom and United States. Ryo Ko's co-authors include Kazuhisa Takahashi, Hirotsugu Kenmotsu, Akira Ono, Toshiaki Takahashi, Haruyasu Murakami, Takehito Shukuya, Tateaki Naito, Kazushige Wakuda, Tetsuhiko Taira and Masahiro Endo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Ryo Ko

53 papers receiving 544 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryo Ko Japan	12	392	299	122	87	39	60	547
Kentaro Ito Japan	14	473 1.2×	400 1.3×	213 1.7×	112 1.3×	27 0.7×	66	699
Ichiro Nakachi Japan	13	374 1.0×	263 0.9×	269 2.2×	138 1.6×	16 0.4×	34	629
Shinichiro Shimamatsu Japan	12	277 0.7×	352 1.2×	175 1.4×	89 1.0×	22 0.6×	40	580
Jan Nyrop Jakobsen Denmark	10	284 0.7×	195 0.7×	153 1.3×	111 1.3×	9 0.2×	18	474
Atsushi Nagase Japan	8	228 0.6×	210 0.7×	135 1.1×	43 0.5×	35 0.9×	22	383
Yoshiro Nakahara Japan	12	255 0.7×	282 0.9×	55 0.5×	54 0.6×	14 0.4×	42	414
Sakiko Otani Japan	13	404 1.0×	465 1.6×	142 1.2×	92 1.1×	7 0.2×	45	613
Jérôme Alexandre France	3	174 0.4×	139 0.5×	296 2.4×	78 0.9×	22 0.6×	4	445
Giorgia Guaitoli Italy	12	162 0.4×	229 0.8×	146 1.2×	121 1.4×	37 0.9×	27	436
Serena Ricciardi Italy	11	287 0.7×	342 1.1×	178 1.5×	59 0.7×	12 0.3×	27	545

Countries citing papers authored by Ryo Ko

Since Specialization

Citations

This map shows the geographic impact of Ryo Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryo Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryo Ko more than expected).

Fields of papers citing papers by Ryo Ko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryo Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryo Ko. The network helps show where Ryo Ko may publish in the future.

Co-authorship network of co-authors of Ryo Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Ryo Ko. A scholar is included among the top collaborators of Ryo Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryo Ko. Ryo Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nishioka, Naoya, Tateaki Naito, Takashi Sugino, et al.. (2025). Desensitizing Effect of Intra‐Tumoral GDF‐15 on Immunotherapy in Patients With Advanced Non‐Small Cell Lung Cancer. Thoracic Cancer. 16(10). e70089–e70089.

Naito, Tateaki, Keita Miura, Nobuaki Mamesaya, et al.. (2025). Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer. Thoracic Cancer. 16(12). e70104–e70104. 1 indexed citations

Naito, Tateaki, Haruyasu Murakami, Shota Omori, et al.. (2025). Correlation between cancer cachexia and psychosocial impact in older patients with advanced lung cancer undergoing chemotherapy. Asia-Pacific Journal of Oncology Nursing. 12. 100658–100658.

Mouri, Atsuto, Ryo Ko, Tomonori Makiguchi, et al.. (2024). A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A. ESMO Open. 9(10). 103939–103939. 1 indexed citations

Naito, Tateaki, Keita Miura, Yuko Iida, et al.. (2024). Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study. Thoracic Cancer. 15(25). 1831–1841. 2 indexed citations

Saito, Go, Ryo Ko, Yuki Shiko, et al.. (2024). A retrospective study of 157 patients comparing platinum-anthracycline to other platinum combination for untreated unresectable thymoma: NEJ023B.. Journal of Clinical Oncology. 42(16_suppl). 8111–8111.

Murakami, Haruyasu, Nobuaki Mamesaya, Shota Omori, et al.. (2024). Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer. Thoracic Cancer. 15(21). 1665–1672. 1 indexed citations

Iida, Yuko, Kazushige Wakuda, Hirotsugu Kenmotsu, et al.. (2024). Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma. Scientific Reports. 14(1). 7641–7641. 1 indexed citations

Iida, Yuko, Kazushige Wakuda, Takuya Kawata, et al.. (2024). Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer. Thoracic Cancer. 15(6). 477–485. 2 indexed citations

10.

Murakami, Haruyasu, Keita Miura, Yuko Iida, et al.. (2023). Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer. Thoracic Cancer. 14(35). 3475–3482. 1 indexed citations

11.

Saito, Ryota, Shunichi Sugawara, Ryo Ko, et al.. (2023). Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. European Journal of Cancer. 185. 83–93. 16 indexed citations

12.

Saito, Ryota, Shunichi Sugawara, Ryo Ko, et al.. (2023). Phase 2 Study of Osimertinib in Combination with Platinum and Pemetrexed in Patients with Previously Untreated EGFR–Mutated Advanced Non–Squamous Non–Small Cell Lung Cancer: The OPAL Study. SSRN Electronic Journal. 1 indexed citations

13.

Asao, Tetsuhiko, Takehito Shukuya, Yasushi Goto, et al.. (2023). Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101). Clinical Lung Cancer. 24(7). e247–e253. 4 indexed citations

14.

Miyauchi, Eisaku, Satoshi Morita, Atsushi Nakamura, et al.. (2022). Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR. Journal of Clinical Oncology. 40(31). 3587–3592. 53 indexed citations

15.

Nishioka, Naoya, Tateaki Naito, Taichi Miyawaki, et al.. (2022). Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer. Thoracic Cancer. 13(10). 1496–1504. 12 indexed citations

16.

Omori, Shota, Takanori Kawabata, Naoya Nishioka, et al.. (2022). Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy. Advances in Radiation Oncology. 8(2). 101129–101129. 4 indexed citations

17.

Miyawaki, Taichi, Hirotsugu Kenmotsu, Naoya Nishioka, et al.. (2022). Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer. Cancer Medicine. 12(2). 1451–1460. 4 indexed citations

18.

Morita, Ryo, Hajime Asahina, Kentaro Tanaka, et al.. (2020). 382MO The preliminary safety result of a phase II study of osimertinib in combination with platinum + pemetrexed in patients with previously untreated EGFR-mutated advanced NSCLC (NEJ032C/LOGIK1801: OPAL). Annals of Oncology. 31. S1390–S1390. 1 indexed citations

19.

Watanabe, Masaru, Hirotsugu Kenmotsu, Ryo Ko, et al.. (2018). Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. Cancer Science. 109(8). 2539–2548. 32 indexed citations

20.

Takahashi, Fumiyuki, Motoyasu Kato, Yoichiro Mitsuishi, et al.. (2018). Dasatinib Suppresses TGFβ-Mediated Epithelial–Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis. Lung. 196(5). 531–541. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact